Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomography-staged, Castration-sensitive Oligometastatic Prostate Cancer: The OLI-P Phase 2 Clinical Trial.
暂无分享,去创建一个
S. Löck | M. Krause | D. Zips | F. Lohaus | F. Paulsen | J. Kotzerke | K. Zöphel | Christian Thomas | A. Müller | T. Hölscher | M. Baumann | L. Koi | Manfred Wirth | M. Wirth | C. Thomas
[1] R. Bristow,et al. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. , 2021, European urology.
[2] M. Krause,et al. Metastatic Spread in Prostate Cancer Patients Influencing Radiotherapy Response , 2021, Frontiers in Oncology.
[3] A. Afshar-Oromieh,et al. Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis , 2021, European Journal of Nuclear Medicine and Molecular Imaging.
[4] R. Weichselbaum,et al. (Oligo)metastasis as a Spectrum of Disease , 2021, Cancer Research.
[5] A. Kishan,et al. Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome. , 2020, European urology focus.
[6] P. Vermeulen,et al. Stereotactic ablative radiation therapy to all lesions in patients with oligometastatic cancers: a phase I dose-escalation trial. , 2020, International journal of radiation oncology, biology, physics.
[7] H. G. van der Poel,et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2020, European urology.
[8] Sean S. Park,et al. Patterns of recurrence and modes of progression after metastasis-directed therapy in oligometastatic castration-sensitive prostate cancer , 2020, International journal of radiation oncology, biology, physics.
[9] N. Lawrentschuk,et al. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. , 2020, European urology.
[10] B. Yaremko,et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial , 2020, medRxiv.
[11] Ash A. Alizadeh,et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer , 2020, JAMA oncology.
[12] A. Campbell,et al. A Multicenter Prospective Clinical Trial of 68Gallium PSMA HBED-CC PET-CT Restaging in Biochemically Relapsed Prostate Carcinoma: Oligometastatic Rate and Distribution Compared With Standard Imaging. , 2019, International journal of radiation oncology, biology, physics.
[13] J. Lee,et al. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] M. Wirth,et al. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? , 2019, European urology.
[15] P. Boutros,et al. What Is Oligometastatic Prostate Cancer? , 2019, European urology focus.
[16] W. Everaerts,et al. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review. , 2019, European urology oncology.
[17] H. G. van der Poel,et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. , 2019, European urology.
[18] R. Weichselbaum,et al. Oligometastatic prostate cancer: Reality or figment of imagination? , 2018, Cancer.
[19] N. Lawrentschuk,et al. Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial. , 2018, European urology.
[20] L. Collette,et al. Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. , 2018, The Lancet. Oncology.
[21] U. Harmenberg,et al. Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005-2014. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[22] E. Goetghebeur,et al. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] T. Treasure,et al. Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial , 2017 .
[24] G. Jenster,et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. , 2017, European urology.
[25] J. Attia,et al. Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[26] A. D'Amico,et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. , 2015, European urology.
[27] N. Lumen,et al. Prognostic factors influencing prostate cancer‐specific survival in non‐castrate patients with metastatic prostate cancer , 2014, The Prostate.
[28] T. Derlin,et al. Patterns of Progression After 68Ga-PSMA-Ligand PET/CT-Guided Radiation Therapy for Recurrent Prostate Cancer. , 2019, International journal of radiation oncology, biology, physics.
[29] P. Iyengar,et al. Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial , 2018, JAMA oncology.
[30] Merina Ahmed,et al. Stereotactic body radiotherapy for oligometastases. , 2013, The Lancet. Oncology.